SEATTLE--(BUSINESS WIRE)--May 4, 2016--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced that the company will issue its first
quarter 2016 financial results for the period ended March 31, 2016, on
Tuesday, May 10, 2016, before the market opens. Omeros management will
host a conference call and webcast that day at 9:00 a.m. Eastern Time
(6:00 a.m. Pacific Time) to discuss the financial results.
Conference Call Details
To access the live conference call
via phone, please dial (844) 831-4029 from the United States and Canada
or (920) 663-6278 internationally. The participant passcode is 5866590.
Please dial in approximately 10 minutes prior to the start of the call.
A telephone replay will be available for one week following the call and
may be accessed by dialing (855) 859-2056 from the United States and
Canada or (404) 537-3406 internationally. The replay passcode is 5866590.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and go to “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a biopharmaceutical
company committed to discovering, developing and commercializing both
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, coagulopathies and disorders
of the central nervous system. Derived from its proprietary
PharmacoSurgery® platform, the company’s first drug product,
OMIDRIA® (phenylephrine and ketorolac injection) 1%/0.3%, was
broadly launched in the U.S. in April 2015 for use during cataract
surgery or intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the European Union, the European
Commission has approved OMIDRIA for use in cataract surgery and lens
replacement procedures to maintain mydriasis (pupil dilation), prevent
miosis (pupil constriction), and to reduce postoperative eye pain.
Omeros has five clinical-stage development programs focused on:
complement-related thrombotic microangiopathies; complement-mediated
glomerulopathies; Huntington’s disease and cognitive impairment;
addictive and compulsive disorders; and preventing problems associated
with urologic surgical procedures. In addition, Omeros has a proprietary
GPCR platform, which is making available an unprecedented number of new
GPCR drug targets and corresponding compounds to the pharmaceutical
industry for drug development, and a platform used to generate
View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005674/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams
and Media Relations